UBS AM’s Neumora Therapeutics NMRA Stock Holding History

UBS AM’s Portfolio NMRA Stock Details NMRA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-72,622	Closed	-$770K	–	2681
2024 Q4	$770K	Buy	+72,622	New	+$870K	﹤0.01%	2457

Other funds holding NMRA

SoftBank Group Tokyo, Japan $11.4B AUM 27.91% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

MCMU

MIC Capital Management (UK) London, United Kingdom $352M AUM 0.23% 1-Year Est. Return

Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wellcome Trust London, United Kingdom $9.01B AUM 12.05% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Iconiq Capital San Francisco, California $4.46B AUM 22.86% 1-Year Est. Return

Lunate Capital Al Maryah Island, Abu Dhabi, United Arab Emirates $120M AUM 72.64% 1-Year Est. Return

UBS AM's NMRA Position: Q1 2025 in Review

UBS AM sold out of Neumora Therapeutics (NMRA) in Q1 2025, closing a stake of 72,622 shares — an estimated $770K sold.

UBS AM first reported a position in NMRA in Q4 2024 and held it in 1 quarter. The position peaked at $770K in Q4 2024. 115 funds tracked by Wall St. Rank hold NMRA as of Q1 2025.

UBS AM reported no remaining Neumora Therapeutics position as of Q1 2025 after selling out during the quarter.
UBS AM sold 72,622 Neumora Therapeutics shares in Q1 2025, an estimated $770K.
UBS AM first reported a position in Neumora Therapeutics in Q4 2024 and held it in 1 quarter.
UBS AM's Neumora Therapeutics position peaked at $770K in Q4 2024.
115 funds tracked by Wall St. Rank held Neumora Therapeutics as of Q1 2025.

Based on UBS AM's 13F filing for Q1 2025, filed 19 May 2025.